Loading…
Xenon Pharmaceuticals Inc. is projected to rise to $80.26 by 2027, a +19% move from its current price of $67.51. XENE is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $65.87 | $67.53 | $69.23 | +0.04% |
| Jul 13 | $65.22 | $67.55 | $69.97 | +0.07% |
| Jul 14 | $64.73 | $67.58 | $70.55 | +0.11% |
| Jul 15 | $64.33 | $67.60 | $71.05 | +0.14% |
| Jul 16 | $63.97 | $67.63 | $71.49 | +0.18% |
| Jul 17 | $63.66 | $67.65 | $71.90 | +0.22% |
| Jul 18 | $63.37 | $67.68 | $72.27 | +0.25% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $63.37 | $67.68 | $72.27 | +0.25% |
| Week 2 | $61.82 | $67.85 | $74.46 | +0.51% |
| Week 3 | $60.70 | $68.02 | $76.22 | +0.76% |
| Week 4 | $59.79 | $68.19 | $77.78 | +1.02% |
| Week 5 | $59.02 | $68.37 | $79.19 | +1.28% |
| Week 6 | $58.35 | $68.54 | $80.51 | +1.53% |
| Week 7 | $57.74 | $68.71 | $81.77 | +1.79% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company that engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression.
In addition, the company’s Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy.
Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Xenon Pharmaceuticals Inc. (XENE) is the asset; current price $69.95, market cap $6.76B, ranked 1144 by market capitalization. The stock sits in the Healthcare sector as a neuroscience-focused biopharmaceutical company.
A major floor 37.9% below — a decisive break under it would weaken the trend.
The nearest floor, 24.1% below — buyers have tended to step in here.
The nearest ceiling, 5.1% above — a clean break opens room to run.
A major ceiling 23.6% above — clearing it would confirm fresh momentum.
Key XENE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of XENE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $66.75 | Buy | $67.23 | Buy |
| MA 10 | $63.52 | Buy | $64.17 | Buy |
| MA 20 | $58.59 | Buy | $60.67 | Buy |
| MA 50 | $56.20 | Buy | $57.18 | Buy |
| MA 100 | $54.58 | Buy | $54.13 | Buy |
| MA 200 | $48.12 | Buy | $49.62 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 77.00 | Sell |
| Stoch RSI (14) | 70.20 | Neutral |
| CCI (20) | 139.59 | Buy |
| Williams %R (14) | -12.48 | Info |
| MACD (12,26,9) | 1.45 | Buy |
| ROC (12) | 26.20 | Buy |
| Bollinger %B (20,2) | 0.94 | Neutral |
| Stochastic %K (14) | 87.52 | Sell |
| TRIX (15) | 0.56 | Buy |
| Awesome (5,34) | 10.37 | Buy |
| Ultimate (7,14,28) | 81.70 | Sell |
| Momentum (10) | 12.14 | Buy |
| Aroon Osc (25) | 84.00 | Buy |
| Hull MA (9) | 71.32 | Sell |
| ADX (14) | 35.07 | Buy |
| ATR (14) | 1.36 | Info |
The current technical picture is colored by bullish sentiment on the near term. RSI14 is 90, indicating strong momentum, while the 50-day moving average stands at $55.58 and the 200-day moving average at $47.79.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $39.98 | $67.51 | $92.01 | 0% | Neutral | |
| $64.43 | $80.26 | $105.44 | +19% | Neutral | |
| $70.08 | $89.52 | $121.69 | +33% | Bullish | |
| $88.68 | $115.67 | $161.48 | +71% | Bullish | |
| $103.71 | $137.76 | $196.71 | +104% | Bullish | |
| $115.81 | $156.42 | $227.79 | +132% | Bullish | |
| $123.04 | $168.78 | $250.18 | +150% | Bullish | |
| $122.64 | $170.68 | $257.09 | +153% | Bullish | |
| $141.64 | $199.86 | $305.52 | +196% | Bullish | |
| $161.85 | $231.40 | $358.61 | +243% | Bullish | |
| $226.20 | $343.15 | $563.38 | +408% | Bullish | |
| $462.82 | $776.65 | $1,387.46 | +10.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $39.98 | $67.51 | $82.11 | +0.00% |
| August 2026 | $59.76 | $70.38 | $84.99 | +4.26% |
| September 2026 | $58.87 | $69.77 | $85.12 | -0.86% |
| October 2026 | $59.46 | $70.85 | $87.17 | +1.54% |
| November 2026 | $61.43 | $73.54 | $91.13 | +3.80% |
| December 2026 | $61.36 | $73.76 | $92.01 | +0.31% |
Click any year to see its month-by-month XENE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect XENE to range from $39.98 to $92.01 through 2026. The $67.51 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The XENE price prediction for 2027 points to an average of $80.26 (low $64.43, high $105.44) — a potential gain of +19% on today's $67.51. Price action looks broadly range-bound.
In 2028, XENE is projected to trade between $70.08 and $121.69, averaging $89.52 — a potential gain of +33% from today's $67.51. That is up +12% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Xenon Pharmaceuticals Inc.'s 2029 outlook centres on $115.67, within a $88.68 to $161.48 range. That is up +29% on the projected 2028 average. That marks a +71% change versus current levels. Momentum favours further upside here.
By 2030, XENE could reach as high as $196.71, with a base case around $137.76 and support toward $103.71 — roughly +104% from $67.51. Buyers look set to stay in control over this stretch.
Expect XENE to range from $115.81 to $227.79 through 2031. The $156.42 average target implies a +132% move from current prices. That is up +14% on the projected 2030 average. Momentum favours further upside here.
The XENE price prediction for 2032 points to an average of $168.78 (low $123.04, high $250.18) — a potential gain of +150% on today's $67.51. Buyers look set to stay in control over this stretch.
In 2033, XENE is projected to trade between $122.64 and $257.09, averaging $170.68 — a potential gain of +153% from today's $67.51. That is up +1% on the projected 2032 average. Momentum favours further upside here.
Xenon Pharmaceuticals Inc.'s 2034 outlook centres on $199.86, within a $141.64 to $305.52 range. That is up +17% on the projected 2033 average. That marks a +196% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, XENE could reach as high as $358.61, with a base case around $231.40 and support toward $161.85 — roughly +243% from $67.51. Momentum favours further upside here.
Expect XENE to range from $226.20 to $563.38 through 2040. The $343.15 average target implies a +408% move from current prices. That is up +48% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The XENE price prediction for 2050 points to an average of $776.65 (low $462.82, high $1,387.46) — a potential gain of +10.5x on today's $67.51. Momentum favours further upside here.
Investing $1,000 in XENE today (≈ 14.813718 XENE) could be worth
$11,505.06
+$10,505.06 (+1051%) by 2050 · US Dollar
Based on the average projected XENE price of $776.65 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in XENEwould be worth at today's price.
$1,000 invested in XENE on Jul 10, 2025 (≈ 30.321407 XENE) would be worth
$2,046.85
+$1,046.85 (+104.7%) today · 2.05× · US Dollar
Based on a XENE entry price of $32.98 vs. today's $67.51.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $60.96 | $1,107.37 | +10.7% |
| 1 month ago | $51.34 | $1,314.86 | +31.5% |
| 3 months ago | $58.4 | $1,155.91 | +15.6% |
| 6 months ago | $41.23 | $1,637.28 | +63.7% |
| 1 year ago | $32.98 | $2,046.85 | +104.7% |
| All time (5.0y) ago | $18.41 | $3,666.76 | +266.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our XENE forecast.
Our base-case forecast reaches $140.00 around 2031.
Implied market cap at $140.00: $13.53B
The multi-year forecast shows a rising trajectory in average prices: 2026 avg $69.95 (min $39.98, max $95.08), 2027 avg $82.18 (min $65.82, max $108.29), 2028 avg $90.95 (min $71.00, max $124.08), 2029 avg $116.73 (min $89.20, max $163.64), 2030 avg $138.88 (min $104.15, max $199.22) with an ROI of 98.5. The outlook continues to improve in later years with 2031 avg $156.90 (min $115.67, max $229.63) and 2032 avg $168.07 (min $121.94, max $250.44), then 2033 avg $169.42 (min $121.11, max $256.61), 2034 avg $197.68 (min $139.33, max $303.96), and 2035 avg $227.42 (min $158.13, max $354.60). By 2040 the avg is $334.23 with a 377.8 ROI and by 2050 the avg reaches $747.80 with a 969 ROI.
Sentiment shifts to BULLISH from 2028 onward, reflecting an expanding price route and stronger long-term growth potential, albeit with the usual uncertainty around future outcomes.
Tap a question to reveal the answer.
In 2030 the forecast shows min $104.15, avg $138.88, max $199.22 with a predicted ROI of 98.5 and a bullish sentiment.
Forecasts imply a rising trajectory in average prices across years, with 2030 avg $138.88 and 2040 avg $334.23, culminating in 2050 avg $747.80. ROI progresses to 98.5 in 2030 and to 969 in 2050, with sentiment turning bullish in later years.
The 2030 max is $199.22, which is just under $200. The 2040 max is $552.63, indicating higher potential later in the forecast.
Current price is $69.95 and market cap is $6.76B, with a market-rank of 1144.
Bullish sentiment is indicated, with RSI14 at 90. SMA50 at $55.58 and SMA200 at $47.79. Support is at $51.21 and resistance at $69.95, with a 30-day price range of $59.15 to $82.72.
Xenon Pharmaceuticals Inc. Community Discussion
0Share your Xenon Pharmaceuticals Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.